Treatment failure associated with HCV resistance to newly developed direct-acting
antiviral agents is not an uncommon occurrence and poses a substantial problem to
clinicians trying to re-treat patients who have failed available interferon-free
treatments. A new study suggests that host-targeted agents are the way forward, but is
this approach really feasible?